The JAK2
V617F point mutation has been described in 65-97% of patients with polycythemia vera (PV). 1 Previously, 17 phenotypical cases of PV from a large group of patients from three institutions were initially reported as JAK2 V617F negative. 2 These cases were reanalyzed in detail to determine the cause, if any, of the JAK2 V617F negativity. Reasons for this initial negativity included inaccurate clinical diagnosis, relatively insensitive laboratory techniques, insufficient material for retesting, and possible treatment effect. It was predicted that when tested appropriately, JAK2 mutations would be found in all new cases of PV. 2 To address the assay sensitivity issue, we studied a total of 105 PV cases diagnosed by Polycythemia Vera Study Group criteria using three different assays of distinct analytical sensitivity. We defined the sensitivity by mixing DNA from JAK2 V617F -containing human erythroid leukemia cells (HEL) with that from normal peripheral blood mononuclear cells, so that 1% sensitivity would detect one part of HEL DNA in 100 parts of normal DNA. The first method used was pyrosequencing, which involves synthetic nucleotide extension by DNA polymerase. The method reliably detects JAK2 V617F when the mutant allele is greater than 5%. 1 The second method was a standard amplification refractory mutation system (ARMS) PCR assay, which detects the mutant allele when it occupies more than 1% of total DNA. 3 The third method was a modified highly sensitive ARMS assay. 4 The analytic sensitivity of the modified ARMS assay reaches 0.1% and has a false positive rate of less than 0.01% (we found 1 positive case in 300 individuals without myeloid disorders). 5 Of 105 PV cases, the combination of all three assays detected the JAK2 V617F allele in 104. In the remaining case, the JAK2 exon 12 deletion (E543-D544 del) was detected. Therefore, mutations in JAK2 have been detected in 100% of 105 PV patients examined.
Of the eight patients who were not detected by the pyrosequencing method, all had been treated; four had been on interferon for a median of 13 years, two on imatinib for 3 years and two had been treated by phlebotomy for 7 and 28 months, respectively. Therefore, sensitive methods such as ARMS-PCR assays presented here may be of particular value in patients treated for some time with different modalities.
Although it has been realized that a sensitive assay is required to identify the JAK2 V617F mutation in PV patients, 2 it has never been shown which level of sensitivity is adequate, that is 5, 1 or 0.1%. To address this issue, in 33 patients, we compared the test results in parallel with three assays. Of these patients, modified ARMS detected JAK2 V617F in all 33 (100%), whereas standard ARMS detected JAK2 V617F in 30 (91%) and pyrosequencing detected JAK2 V617F in 27 (82%). Our results suggest that an assay with 0.1% sensitivity is required to detect adequately JAK2 V617F in all PV patients. These results also suggest that an assay with a sensitivity of 5%, as currently offered by many laboratories, might miss a number of PV patients, especially those who have been treated. 
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